Stock Track | Exelixis Soars 9.32% Intraday on Analyst Upgrades and Strong Q1 Earnings

Stock Track05-07

Exelixis (EXEL) stock surged 9.32% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.

The sharp rise appears to be driven by a wave of positive analyst sentiment and the company's robust first-quarter financial results. Multiple investment firms, including TD Cowen, Goldman Sachs, Morgan Stanley, Stifel, and Wells Fargo, issued or maintained favorable ratings on the stock, with several raising their price targets. This analyst optimism follows Exelixis's report of strong Q1 2026 results, which showed revenue of $610.81 million and net income of $210.47 million, indicating improved operational efficiency.

Investors are also focusing on the strength of the company's CABOMETYX franchise and the regulatory progress of its next-generation therapy, zanzalintinib. The U.S. FDA has accepted a New Drug Application for zanzalintinib, with a key decision date set for December 2026, providing a potential future catalyst for the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111133717?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 03:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111133717","market":"nz","top_or_hot":-1,"title":"Stock Track | Exelixis Soars 9.32% Intraday on Analyst Upgrades and Strong Q1 Earnings","media":"Stock Track","content":"<p>Exelixis (EXEL) stock surged 9.32% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.</p><p>The sharp rise appears to be driven by a wave of positive analyst sentiment and the company's robust first-quarter financial results. Multiple investment firms, including TD Cowen, Goldman Sachs, Morgan Stanley, Stifel, and Wells Fargo, issued or maintained favorable ratings on the stock, with several raising their price targets. This analyst optimism follows Exelixis's report of strong Q1 2026 results, which showed revenue of $610.81 million and net income of $210.47 million, indicating improved operational efficiency.</p><p>Investors are also focusing on the strength of the company's CABOMETYX franchise and the regulatory progress of its next-generation therapy, zanzalintinib. The U.S. FDA has accepted a New Drug Application for zanzalintinib, with a key decision date set for December 2026, providing a potential future catalyst for the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Exelixis Soars 9.32% Intraday on Analyst Upgrades and Strong Q1 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Exelixis Soars 9.32% Intraday on Analyst Upgrades and Strong Q1 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 03:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Exelixis (EXEL) stock surged 9.32% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.</p><p>The sharp rise appears to be driven by a wave of positive analyst sentiment and the company's robust first-quarter financial results. Multiple investment firms, including TD Cowen, Goldman Sachs, Morgan Stanley, Stifel, and Wells Fargo, issued or maintained favorable ratings on the stock, with several raising their price targets. This analyst optimism follows Exelixis's report of strong Q1 2026 results, which showed revenue of $610.81 million and net income of $210.47 million, indicating improved operational efficiency.</p><p>Investors are also focusing on the strength of the company's CABOMETYX franchise and the regulatory progress of its next-generation therapy, zanzalintinib. The U.S. FDA has accepted a New Drug Application for zanzalintinib, with a key decision date set for December 2026, providing a potential future catalyst for the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXEL","symbol_name":"伊克力西斯","start_time":0,"source_url":"","article_id":"1111133717","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111133717","pubTimestamp":1778094348,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Exelixis (EXEL) stock surged 9.32% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.The sharp rise appears to be driven by a wave of positive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXEL":"伊克力西斯"},"translate_title":"个股追踪|Exelixis盘中大涨9.32%，因分析师上调评级和强劲的Q1盈利","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":1},"content_text":"Exelixis (EXEL) stock surged 9.32% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.The sharp rise appears to be driven by a wave of positive analyst sentiment and the company's robust first-quarter financial results. Multiple investment firms, including TD Cowen, Goldman Sachs, Morgan Stanley, Stifel, and Wells Fargo, issued or maintained favorable ratings on the stock, with several raising their price targets. This analyst optimism follows Exelixis's report of strong Q1 2026 results, which showed revenue of $610.81 million and net income of $210.47 million, indicating improved operational efficiency.Investors are also focusing on the strength of the company's CABOMETYX franchise and the regulatory progress of its next-generation therapy, zanzalintinib. The U.S. FDA has accepted a New Drug Application for zanzalintinib, with a key decision date set for December 2026, providing a potential future catalyst for the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111133717","isCrawlerRequest":true}